lobbying_activities: 2599824

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2599824	fcee1c35-ff3a-48d0-9d46-d2f208ec2d2e	Q1	KOUNTOUPES DENHAM CARR & REID, LLC	320918	ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN)	2021	first_quarter	PHA	Issues related to generic pharmaceuticals and biosimilars, including H.R. 928, the BLOCKING Act of 2019. Reimbursement rate for biosimilars. Issues related to the implementation of H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021. Issues related to H.R. 1319, The American Rescue Plan. Issues related to the pharmaceutical supply chain and domestic manufacturing. Issues related to H.R. 6179, Increasing Access to Biosimilars Act of 2020, H.R. 4597, the ACCESS Act, and H.R. 4455, the Biosim Act.	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2021-04-18T14:12:06.457000-04:00